vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and BlueLinx Holdings Inc. (BXC). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $748.9M, roughly 1.3× BlueLinx Holdings Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs 0.2%, a 0.5% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 0.2%). BlueLinx Holdings Inc. produced more free cash flow last quarter ($52.7M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 2.5%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
BlueLinx Holdings Inc. is a wholesale distributor of building and industrial products in the United States. Headquartered in Atlanta, Georgia, Shyam Reddy serves as its President and CEO.
ASTH vs BXC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $748.9M |
| Net Profit | $6.6M | $1.7M |
| Gross Margin | — | 14.4% |
| Operating Margin | 1.9% | 1.3% |
| Net Margin | 0.7% | 0.2% |
| Revenue YoY | 42.9% | 0.2% |
| Net Profit YoY | 184.4% | -89.7% |
| EPS (diluted) | $0.12 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | — | ||
| Q3 25 | $956.0M | $748.9M | ||
| Q2 25 | $654.8M | $780.1M | ||
| Q1 25 | $620.4M | $709.2M | ||
| Q4 24 | $665.2M | $710.6M | ||
| Q3 24 | $478.7M | $747.3M | ||
| Q2 24 | $486.3M | $768.4M | ||
| Q1 24 | $404.4M | $726.2M |
| Q4 25 | $6.6M | — | ||
| Q3 25 | $373.0K | $1.7M | ||
| Q2 25 | $9.4M | $4.3M | ||
| Q1 25 | $6.7M | $2.8M | ||
| Q4 24 | $-7.8M | — | ||
| Q3 24 | $16.1M | $16.0M | ||
| Q2 24 | $19.2M | $14.3M | ||
| Q1 24 | $14.8M | $17.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 14.4% | ||
| Q2 25 | — | 15.3% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | — | 15.9% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 17.6% |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 2.0% | 1.3% | ||
| Q2 25 | 3.1% | 1.9% | ||
| Q1 25 | 3.3% | 1.5% | ||
| Q4 24 | 0.1% | 1.7% | ||
| Q3 24 | 5.9% | 3.2% | ||
| Q2 24 | 6.2% | 3.1% | ||
| Q1 24 | 7.5% | 3.8% |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 1.4% | 0.6% | ||
| Q1 25 | 1.1% | 0.4% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 3.4% | 2.1% | ||
| Q2 24 | 3.9% | 1.9% | ||
| Q1 24 | 3.7% | 2.4% |
| Q4 25 | $0.12 | — | ||
| Q3 25 | $0.01 | $0.20 | ||
| Q2 25 | $0.19 | $0.54 | ||
| Q1 25 | $0.14 | $0.33 | ||
| Q4 24 | $-0.14 | $0.67 | ||
| Q3 24 | $0.33 | $1.87 | ||
| Q2 24 | $0.40 | $1.65 | ||
| Q1 24 | $0.31 | $2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $429.4M |
| Total DebtLower is stronger | — | $598.5M |
| Stockholders' EquityBook value | $779.3M | $623.0M |
| Total Assets | $2.2B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | $429.4M | ||
| Q2 25 | $342.1M | $386.8M | ||
| Q1 25 | $260.9M | $449.0M | ||
| Q4 24 | $290.8M | $505.6M | ||
| Q3 24 | $350.3M | $526.3M | ||
| Q2 24 | $327.7M | $491.4M | ||
| Q1 24 | $337.3M | $481.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $598.5M | ||
| Q2 25 | — | $596.4M | ||
| Q1 25 | — | $596.6M | ||
| Q4 24 | — | $575.1M | ||
| Q3 24 | — | $576.0M | ||
| Q2 24 | — | $574.6M | ||
| Q1 24 | — | $574.0M |
| Q4 25 | $779.3M | — | ||
| Q3 25 | $775.5M | $623.0M | ||
| Q2 25 | $765.5M | $621.3M | ||
| Q1 25 | $745.4M | $636.1M | ||
| Q4 24 | $712.7M | $646.4M | ||
| Q3 24 | $704.6M | $655.6M | ||
| Q2 24 | $678.9M | $652.3M | ||
| Q1 24 | $653.5M | $653.2M |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $1.6B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.2B | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 0.89× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.88× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $58.6M |
| Free Cash FlowOCF − Capex | $-6.0M | $52.7M |
| FCF MarginFCF / Revenue | -0.6% | 7.0% |
| Capex IntensityCapex / Revenue | 0.3% | 0.8% |
| Cash ConversionOCF / Net Profit | -0.44× | 35.42× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $-25.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $10.0M | $58.6M | ||
| Q2 25 | $90.9M | $-26.8M | ||
| Q1 25 | $16.6M | $-33.9M | ||
| Q4 24 | $-10.9M | $18.7M | ||
| Q3 24 | $34.0M | $61.8M | ||
| Q2 24 | $23.2M | $35.8M | ||
| Q1 24 | $6.0M | $-31.1M |
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $7.4M | $52.7M | ||
| Q2 25 | $89.5M | $-36.4M | ||
| Q1 25 | $13.6M | $-39.8M | ||
| Q4 24 | $-13.5M | $-1.5M | ||
| Q3 24 | $31.7M | $53.8M | ||
| Q2 24 | $20.4M | $29.3M | ||
| Q1 24 | $5.6M | $-36.6M |
| Q4 25 | -0.6% | — | ||
| Q3 25 | 0.8% | 7.0% | ||
| Q2 25 | 13.7% | -4.7% | ||
| Q1 25 | 2.2% | -5.6% | ||
| Q4 24 | -2.0% | -0.2% | ||
| Q3 24 | 6.6% | 7.2% | ||
| Q2 24 | 4.2% | 3.8% | ||
| Q1 24 | 1.4% | -5.0% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 0.2% | 1.2% | ||
| Q1 25 | 0.5% | 0.8% | ||
| Q4 24 | 0.4% | 2.9% | ||
| Q3 24 | 0.5% | 1.1% | ||
| Q2 24 | 0.6% | 0.8% | ||
| Q1 24 | 0.1% | 0.8% |
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 35.42× | ||
| Q2 25 | 9.65× | -6.21× | ||
| Q1 25 | 2.48× | -12.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | 3.86× | ||
| Q2 24 | 1.21× | 2.50× | ||
| Q1 24 | 0.40× | -1.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
BXC
| Specialty Products | $525.5M | 70% |
| Structural Products | $223.4M | 30% |
